Last reviewed · How we verify
Tranexamic Acid Injectable Product
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding.
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding. Used for Prevention and treatment of hemorrhage in surgical procedures, Trauma-related hemorrhage, Menorrhagia.
At a glance
| Generic name | Tranexamic Acid Injectable Product |
|---|---|
| Also known as | TXA 100mg/ml, Cyklokapron |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, which are key enzymes in the fibrinolytic cascade responsible for breaking down blood clots. By inhibiting these enzymes, the drug stabilizes fibrin clots and reduces fibrin degradation, leading to decreased bleeding. It is used to prevent or reduce blood loss in surgical and trauma settings.
Approved indications
- Prevention and treatment of hemorrhage in surgical procedures
- Trauma-related hemorrhage
- Menorrhagia
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Nausea
- Vomiting
- Diarrhea
- Hypotension
Key clinical trials
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Effect of Intravenous Tranexamic Acid on Visual Clarity During Shoulder Arthroscopy in the Beach Chair Position (PHASE4)
- Effect of TXA on Reducing Bruising After Filler Injection (PHASE2)
- Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery (EARLY_PHASE1)
- TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study (EARLY_PHASE1)
- Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2) (NA)
- Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: